Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation
- PMID: 28705921
- DOI: 10.1136/ebmed-2017-110764
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation
Keywords: cardiology.
Conflict of interest statement
Competing interests: GYHL is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi Sankyo. No fees are received personally.
Comment on
-
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.Gastroenterology. 2017 Apr;152(5):1014-1022.e1. doi: 10.1053/j.gastro.2016.12.018. Epub 2016 Dec 30. Gastroenterology. 2017. PMID: 28043907
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources